AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer ...

By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...

Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter ...

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

Rep. Alexandria Ocasio-Cortez (AOC) sharply criticised major pharmaceutical companies during a Health Subcommittee hearing, ...

Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a ...

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...

AstraZeneca pays $600M for global rights to Dizal’s lung cancer drug Zegfrovy, boosting its oncology pipeline.

July 9 () - AstraZeneca ‌said on ‌Thursday that ​its drug Wainua, made ‌in ⁠partnership with Ionis, ⁠failed to ​meet ​the ...